Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated in adults for symptomatic treatment of spasmodic torticollis
Please click here to see the full therapeutic indications.
Cervical Dystonia
Tackling the capacity challenge in your clinics with Dysport®
7 minutes
Dr Jonathan Evans discusses Dysport® time to retreatment in clinical trials and how moving to Dysport® may allow adult patients with cervical dystonia to avoid unnecessary appointments and contribute to increasing clinic capacity
DYS-UK-008738
Making sense of the changing NHS and funding flows
12 minutes
Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.
DYS-UK-008730
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. August 2024 DYS-UK-008824
